The American Cancer Society estimates that over 80,000 individuals will be diagnosed with bladder cancer this year.

A large U.S. health records study suggests that difficulty seeing blood in urine may put color-blind patients at higher risk.

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the disease.The ongoing SunRISe-3 trial (NCT05714202) is testing TAR-200 head-to-head ...

Urothelial carcinoma (UC) is the most common cancer of the bladder and urinary tract, but little is known about the many rare subtypes of invasive UC and how best to treat them. "Full understanding of ...

A retrospective cohort study suggested that people with color blindness may have a higher risk of mortality from bladder ...

What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...

WILMINGTON, Del.--(BUSINESS WIRE)--Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab), administered perioperatively in ...

Valar Labs, a leader in AI-powered diagnostics for oncology, today announced a strategic partnership with PathNet Lab, one of the nation’s foremost pathology laboratories. Through this collaboration, ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being over age 55. And the unfortunate reality is that women are often diagnosed at ...

IMFINZI was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings. Further, adding IMFINZI to neoadjuvant chemotherapy was consistent with the ...